Loading...
Please wait, while we are loading the content...
Similar Documents
The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Zhulina, Yaroslava Cao, Yang Amcoff, Karin Carlson, Marie Tysk, Curt Halfvarson, Jonas |
| Copyright Year | 2016 |
| Abstract | BACKGROUND Faecal calprotectin, an established biomarker used to assess mucosal inflammation, has been shown to correlate with endoscopic activity in inflammatory bowel disease (IBD). Longitudinal monitoring of faecal calprotectin, however, has rarely been employed beyond assessment of therapy response and post hoc analyses of clinical trials. AIM To study whether consecutive measurements of faecal calprotectin every third month are useful for monitoring patients with IBD in clinical remission. METHODS Patients aged 18 years or older, with a known diagnosis of IBD in clinical remission, were prospectively studied. Patients provided faecal samples every third month and were prospectively followed until the first clinical relapse or the end of the 2-year follow-up period. Measurements (EK-CAL, Bühlmann Lab. AG, Switzerland) were done at the end of the study. A Cox model with time-dependent covariates was used for analysis. RESULTS Among 104 patients, Crohn's disease (n = 49) and ulcerative colitis (n = 55), 37 had a relapse. A doubling of faecal calprotectin level between two consecutively collected samples was associated with a 101% increased risk of relapse (HR: 2.01; 95% CI: 1.53-2.65; P < 0.001). The relative risk of relapse attenuated with time (HR: 0.80; 95% CI: 0.75-0.86; P < 0.001), by a 20% decrease in risk of relapse per 3-month period since the sample was obtained. CONCLUSIONS By consecutively measuring faecal calprotectin every third month, we quantified the risk of relapse related to faecal calprotectin change and observed attenuation of the risk across time. Our data suggest that longitudinal monitoring of faecal calprotectin is informative in predicting relapse in IBD. |
| Starting Page | 495 |
| Ending Page | 504 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://oru.diva-portal.org/smash/get/diva2:950981/FULLTEXT01.pdf |
| PubMed reference number | 27402063v1 |
| Alternate Webpage(s) | https://doi.org/10.1111/apt.13731 |
| DOI | 10.1111/apt.13731 |
| Journal | Alimentary pharmacology & therapeutics |
| Volume Number | 44 |
| Issue Number | 5 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | 101 Mouse Biological Markers Calcium Carbonate 1250 MG / Cholecalciferol 200 UNT Oral Tablet [Os-Cal 500 with D] Crohn Disease Fecal Incontinence Feces Forty Nine Inactive - Biochemical Activity Level Inflammatory Bowel Diseases Inflammatory disease of mucous membrane Intestinal Diseases Intestines Irritable Bowel Syndrome Leukocyte L1 Antigen Complex Patients Silver Ulcer Ulcerative Colitis |
| Content Type | Text |
| Resource Type | Article |
